Enhancement of antitumor effect using dendritic cells activated with natural killer cells in the presence of Toll-like receptor agonist.
about
Dendritic Cell-Based Cancer Immunotherapy against Multiple Myeloma: From Bench to ClinicCombination therapy with dendritic cells and lenalidomide is an effective approach to enhance antitumor immunity in a mouse colon cancer modelHomotypic NK cell-to-cell communication controls cytokine responsiveness of innate immune NK cellsToll-like receptor 4 activation in cancer progression and therapyImmunotherapy using dendritic cells against multiple myeloma: how to improve?Cellular immunotherapy using dendritic cells against multiple myelomaDendritic cell vaccination with a toll-like receptor agonist derived from mycobacteria enhances anti-tumor immunity.Cellular uptake of exogenous calcineurin B is dependent on TLR4/MD2/CD14 complexes, and CnB is an endogenous ligand of TLR4.Optimal culture conditions for the generation of natural killer cell-induced dendritic cells for cancer immunotherapy.NK cells: key to success of DC-based cancer vaccines?Engineered dendritic cells for gastrointestinal tumor immunotherapy: opportunities in translational research.Anti-tumor Activity of Toll-Like Receptor 7 Agonists.siRNA-induced immunostimulation through TLR7 promotes antitumoral activity against HPV-driven tumors in vivo.Synergistic Antimyeloma Activity of Dendritic Cells and Pomalidomide in a Murine Myeloma Model
P2860
Q27023621-D291AD10-D21C-4012-B0A9-4955B6365535Q33689002-9D6353CD-3980-4102-852A-8D6A874B673DQ34635717-099B78F2-04A0-48E5-86BF-B9B2126141A1Q35550677-82F7CAB2-DD8F-4C60-AA18-99387A397164Q35852574-87F862D7-D15A-45D2-B6E6-14782CD22691Q35865581-C05CCDE8-674E-49CB-BF5E-24DCE51D5FB0Q36545286-B99B9EB4-034F-4E07-A762-0AD4544D608DQ36810015-17CBD498-A566-4507-BC1E-1F96D51E8086Q37729135-7C4BD168-C080-4E10-90E3-8B77FFF66F8AQ38036202-269BB824-2245-4213-B659-F58256396267Q38051671-9CED1294-6BBF-47AE-BC56-65DC4B9A996DQ39377049-303ADB8B-B99C-4D63-A8C3-8C83DAFA5817Q39572943-07247246-8F5B-43DB-9103-11AA9A9B7E91Q58801894-75CE15AB-4549-468E-A611-36FFC87776A9
P2860
Enhancement of antitumor effect using dendritic cells activated with natural killer cells in the presence of Toll-like receptor agonist.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Enhancement of antitumor effec ...... of Toll-like receptor agonist.
@ast
Enhancement of antitumor effec ...... of Toll-like receptor agonist.
@en
type
label
Enhancement of antitumor effec ...... of Toll-like receptor agonist.
@ast
Enhancement of antitumor effec ...... of Toll-like receptor agonist.
@en
prefLabel
Enhancement of antitumor effec ...... of Toll-like receptor agonist.
@ast
Enhancement of antitumor effec ...... of Toll-like receptor agonist.
@en
P2093
P2860
P1476
Enhancement of antitumor effec ...... of Toll-like receptor agonist.
@en
P2093
Byoung Chul Park
Cheol Yi Hong
Deok-Hwan Yang
Hyeong-Rok Kim
Hyeoung-Joon Kim
Ik-Joo Chung
Je-Jung Lee
Joon-Haeng Rhee
Jung-Joon Min
Thanh Nhan Nguyen Pham
P2860
P2888
P304
P356
10.3858/EMM.2010.42.6.042
P577
2010-06-01T00:00:00Z
P5875
P6179
1047506108